Management of epilepsy in pregnancy: What we still need to learn

Safe pregnancies have been a major concern for women with epilepsy. With more than 50 years of research, we have learned that antiseizure medications (ASMs) differ in their teratogenic risk. Valproate is associated with greater risks for malformations and adverse neurodevelopmental outcomes than oth...

Full description

Bibliographic Details
Main Authors: Torbjörn Tomson, Leihao Sha, Lei Chen
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Epilepsy & Behavior Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589986423000424
_version_ 1797400858658340864
author Torbjörn Tomson
Leihao Sha
Lei Chen
author_facet Torbjörn Tomson
Leihao Sha
Lei Chen
author_sort Torbjörn Tomson
collection DOAJ
description Safe pregnancies have been a major concern for women with epilepsy. With more than 50 years of research, we have learned that antiseizure medications (ASMs) differ in their teratogenic risk. Valproate is associated with greater risks for malformations and adverse neurodevelopmental outcomes than other ASMs. Furthermore, seizure control is important for maternal health in pregnancy and it can be affected by a decline in serum concentrations of many ASMs during pregnancy.However, significant knowledge gaps remain. First, there is insufficient evidence about the relative teratogenic risks of most newer generation ASMs, as well as diverse ASM combinations. Similarly, information on gestation-induced changes in maternal serum levels and transfer into breastmilk is inadequate for the majority of the newer ASMs. Further, the optimal dose of folate supplementation remains unknown for women with epilepsy. Finally, most of previous studies on epilepsy and pregnancy come from Europe or North America. Efforts should be made to include more countries in collaboration with existing prospective epilepsy and pregnancy studies to increase the cohort size while at the same time enhancing the generalizability of the results. Large countries, such as China, present great potential to shorten the time to obtain answers to important unsolved questions.
first_indexed 2024-03-09T02:01:40Z
format Article
id doaj.art-49c4f1db3d0e43bfbfb8c45d35a91d13
institution Directory Open Access Journal
issn 2589-9864
language English
last_indexed 2024-03-09T02:01:40Z
publishDate 2023-01-01
publisher Elsevier
record_format Article
series Epilepsy & Behavior Reports
spelling doaj.art-49c4f1db3d0e43bfbfb8c45d35a91d132023-12-08T04:45:51ZengElsevierEpilepsy & Behavior Reports2589-98642023-01-0124100624Management of epilepsy in pregnancy: What we still need to learnTorbjörn Tomson0Leihao Sha1Lei Chen2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SwedenDepartment of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu 610041, SichuanDepartment of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu 610041, Sichuan; Corresponding author.Safe pregnancies have been a major concern for women with epilepsy. With more than 50 years of research, we have learned that antiseizure medications (ASMs) differ in their teratogenic risk. Valproate is associated with greater risks for malformations and adverse neurodevelopmental outcomes than other ASMs. Furthermore, seizure control is important for maternal health in pregnancy and it can be affected by a decline in serum concentrations of many ASMs during pregnancy.However, significant knowledge gaps remain. First, there is insufficient evidence about the relative teratogenic risks of most newer generation ASMs, as well as diverse ASM combinations. Similarly, information on gestation-induced changes in maternal serum levels and transfer into breastmilk is inadequate for the majority of the newer ASMs. Further, the optimal dose of folate supplementation remains unknown for women with epilepsy. Finally, most of previous studies on epilepsy and pregnancy come from Europe or North America. Efforts should be made to include more countries in collaboration with existing prospective epilepsy and pregnancy studies to increase the cohort size while at the same time enhancing the generalizability of the results. Large countries, such as China, present great potential to shorten the time to obtain answers to important unsolved questions.http://www.sciencedirect.com/science/article/pii/S2589986423000424Women with epilepsySafe pregnancyAntiseizure medicationTeratogenic risk
spellingShingle Torbjörn Tomson
Leihao Sha
Lei Chen
Management of epilepsy in pregnancy: What we still need to learn
Epilepsy & Behavior Reports
Women with epilepsy
Safe pregnancy
Antiseizure medication
Teratogenic risk
title Management of epilepsy in pregnancy: What we still need to learn
title_full Management of epilepsy in pregnancy: What we still need to learn
title_fullStr Management of epilepsy in pregnancy: What we still need to learn
title_full_unstemmed Management of epilepsy in pregnancy: What we still need to learn
title_short Management of epilepsy in pregnancy: What we still need to learn
title_sort management of epilepsy in pregnancy what we still need to learn
topic Women with epilepsy
Safe pregnancy
Antiseizure medication
Teratogenic risk
url http://www.sciencedirect.com/science/article/pii/S2589986423000424
work_keys_str_mv AT torbjorntomson managementofepilepsyinpregnancywhatwestillneedtolearn
AT leihaosha managementofepilepsyinpregnancywhatwestillneedtolearn
AT leichen managementofepilepsyinpregnancywhatwestillneedtolearn